Welcome to the Boehringer Ingelheim Pharmaceuticals Inc.(BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.

      On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

      By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. Please review the following prior to submitting a request through our on-line system.

      Medical Education Grants

      A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.

      Please see below for submission timelines:

      • Grant applications must be submitted no less than 60 days prior to the program start date.

      New and Returning Visitors to BIPI/Lilly Medical Grants

      To begin a new application, return to a saved application, or track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/. If this is the first time you are visiting the site, you must register as a New User. An application ID beginning with "ME", will be assigned once you submit the application.

      Educational Objectives - Diabetes

      1. Improve clinicians’ understanding of the current guidelines and scientific evidence supporting management of cardiovascular risk in patients with Type 2 diabetes
      2. Improve clinicians’ understanding and knowledge of optimally managed benefit/risk profiles of treatments for patients with Type 1 Diabetes
      3. Enhance clinicians' awareness and knowledge of emerging scientific evidence regarding treatment of patients with type 2 diabetes patients with or without concomitant heart failure or renal disease
      4. To help improve the insulin experience for people with diabetes and increase clinicians’ understanding of the following:
        a. Insulin Initiation Experience and Barriers
        • Insulin initiation experience, including the underlying causes of psychological insulin resistance
        • Adherence/Persistence
        • Impact of barriers on patient outcomes
        b. Strategies supported by evidence to overcome aforementioned barriers, including emotional support

      Responding to a Request for Educational Grant Application (REGA)
      Throughout the year, the Medical Grants department may announce a Request for Educational Grant Application (REGA). The intent of this announcement is to notify experienced and accredited Continuing Medical Education (CME) providers and accredited Continuing Education (CE) providers that BIPI/Lilly is interested in receiving applications for educational grants for support consideration.

      Grant applications in response to BIPI/Lilly Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi. While REGAs may specify timing of requested responses, BIPI and Lilly will continue to review all grant requests which are received.

      To contact the BIPI/Lilly Alliance Medical Grants Department, please send an email to medgrnts.rdg@boehringer-ingelheim.com.